BR112013024034A2 - composição farmacêutica para tratamento de doença na cavidade oral compreendendo rebamipida - Google Patents

composição farmacêutica para tratamento de doença na cavidade oral compreendendo rebamipida

Info

Publication number
BR112013024034A2
BR112013024034A2 BR112013024034A BR112013024034A BR112013024034A2 BR 112013024034 A2 BR112013024034 A2 BR 112013024034A2 BR 112013024034 A BR112013024034 A BR 112013024034A BR 112013024034 A BR112013024034 A BR 112013024034A BR 112013024034 A2 BR112013024034 A2 BR 112013024034A2
Authority
BR
Brazil
Prior art keywords
rebamipide
pharmaceutical composition
oral cavity
treating oral
cavity disease
Prior art date
Application number
BR112013024034A
Other languages
English (en)
Inventor
Kazushi Sakurai
Nobutomo Sako
Takako Nakashima
Takakuni Matsuda
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112013024034A2 publication Critical patent/BR112013024034A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "composição farmacêutica para tratamento de doença na cavidade oral compreendendo rebamipida". a presente invenção refere-se a uma composição farmacêutica compreendendo rebamipida tendo um tamanho de partícula médio menor que 500 nm, um agente dispersante e um agente de aumento de viscosidade em que o agente de aumento de viscosidade não tem ação agregativa das partículas de rebamipida, que é usada como um gargarejo ou uma preparação líquida para bochechar e engolir compreendendo rebamipida para prevenção e/ou tratamento da estomatite causada por radioterapia.
BR112013024034A 2011-03-24 2012-03-22 composição farmacêutica para tratamento de doença na cavidade oral compreendendo rebamipida BR112013024034A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011066353 2011-03-24
PCT/JP2012/058280 WO2012128394A1 (en) 2011-03-24 2012-03-22 A pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide

Publications (1)

Publication Number Publication Date
BR112013024034A2 true BR112013024034A2 (pt) 2016-12-13

Family

ID=45932481

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013024034A BR112013024034A2 (pt) 2011-03-24 2012-03-22 composição farmacêutica para tratamento de doença na cavidade oral compreendendo rebamipida

Country Status (16)

Country Link
US (1) US20140010882A1 (pt)
EP (1) EP2688552A1 (pt)
JP (2) JP5841167B2 (pt)
KR (1) KR20140020289A (pt)
CN (1) CN103429224A (pt)
AR (1) AR085527A1 (pt)
AU (1) AU2012232062B2 (pt)
BR (1) BR112013024034A2 (pt)
CA (1) CA2829107A1 (pt)
CO (1) CO6801754A2 (pt)
EA (1) EA201391379A1 (pt)
MX (1) MX2013010971A (pt)
SG (1) SG193391A1 (pt)
TW (1) TWI547281B (pt)
UA (1) UA114600C2 (pt)
WO (1) WO2012128394A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015034008A1 (ja) * 2013-09-05 2015-03-12 大塚製薬株式会社 レバミピドの局所止血用途
CN104586762A (zh) * 2014-04-11 2015-05-06 广州仁恒医药科技有限公司 含有瑞巴派特的药物组合物及其制备方法
CN105878245B (zh) * 2015-01-07 2017-12-15 珠海亿胜生物制药有限公司 一种瑞巴派特水悬浮液的制备方法
SI3265140T1 (sl) 2015-03-02 2021-11-30 Medlab Clinical U.S., Inc. Dostavni sistemi za dostavo skozi sluznico ali skozi kožo
CA3059529A1 (en) 2017-04-14 2018-10-18 Capsugel Belgium Nv Process for making pullulan
CN110678170A (zh) 2017-04-14 2020-01-10 比利时胶囊公司 普鲁兰多糖胶囊
KR101923519B1 (ko) 2018-06-26 2019-02-27 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
JP7132774B2 (ja) 2018-07-09 2022-09-07 日綜産業株式会社 移動足場
KR20200019451A (ko) 2018-08-14 2020-02-24 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
EP3797771B1 (en) * 2019-09-03 2022-02-23 Square Power Ltd Rebamipide for use in prophylaxis and treatment of celiac disease
CN114053242A (zh) * 2021-11-19 2022-02-18 苏州天马医药集团天吉生物制药有限公司 一种瑞巴派特片及其制备方法
KR102659338B1 (ko) * 2023-05-18 2024-04-19 국제약품 주식회사 안구건조증 치료용 약제학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69420832T2 (de) 1993-10-21 2000-01-13 Otsuka Pharma Co Ltd Die Verwendung von Carbostyrilderivaten zur Herstellung eines Arzneimittels zur Hemmung der Produktion von Interleukin-8
JP3093661B2 (ja) 1995-10-12 2000-10-03 大塚製薬株式会社 眼疾患治療剤
ES2396598T3 (es) * 2000-08-25 2013-02-22 Senju Pharmaceutical Co., Ltd. Preparaciones en forma de suspensiones acuosas
JP2002255852A (ja) 2001-03-01 2002-09-11 Toa Eiyo Ltd 口内炎用スプレー製剤
DE60211004T2 (de) * 2001-10-10 2006-08-31 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Pulververarbeitung mit unter druck stehenden gasförmigen fluids
US7879877B2 (en) * 2003-07-30 2011-02-01 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives for accelerating salivation
TWI363626B (en) * 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
JP5288791B2 (ja) * 2005-01-28 2013-09-11 武田薬品工業株式会社 難水溶性物質含有微細化組成物
TW200808375A (en) * 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
JP5328789B2 (ja) * 2007-08-10 2013-10-30 大塚製薬株式会社 レバミピドを含有する医薬組成物

Also Published As

Publication number Publication date
TWI547281B (zh) 2016-09-01
JP2014508721A (ja) 2014-04-10
US20140010882A1 (en) 2014-01-09
TW201244718A (en) 2012-11-16
NZ614970A (en) 2016-01-29
JP2016094417A (ja) 2016-05-26
MX2013010971A (es) 2013-10-07
CO6801754A2 (es) 2013-11-29
WO2012128394A1 (en) 2012-09-27
SG193391A1 (en) 2013-10-30
AU2012232062B2 (en) 2017-04-20
JP6101332B2 (ja) 2017-03-22
EP2688552A1 (en) 2014-01-29
CA2829107A1 (en) 2012-09-27
JP5841167B2 (ja) 2016-01-13
AU2012232062A1 (en) 2013-09-26
CN103429224A (zh) 2013-12-04
KR20140020289A (ko) 2014-02-18
EA201391379A1 (ru) 2014-06-30
UA114600C2 (uk) 2017-07-10
AR085527A1 (es) 2013-10-09

Similar Documents

Publication Publication Date Title
BR112013024034A2 (pt) composição farmacêutica para tratamento de doença na cavidade oral compreendendo rebamipida
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
BR112015012197A2 (pt) terapia de combinação
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112015006093A2 (pt) combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington
BR112018014545A2 (pt) probióticos para uso como agentes anti-inflamatórios na cavidade oral
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
BR112013033008A8 (pt) composição farmacêutica líquida compreendendo nitisinona
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112014016472A8 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112012019921A2 (pt) composições líquidas compreendendo um agente de resfriamento não-metol e um espessante para tratamento de um sintoma respiratório.
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
BR112015005942A2 (pt) extratos de cynara scolymus, coffea spp. e olea europaea para tratamento de síndrome metabólica
BR112016007010A2 (pt) composição de higiene oral anidro e método de fabricação de uma mistura de tratamento
BR112013002226A2 (pt) composições para o cuidado oral, livres de fosfato baseadas em agente antibacteriano magnólia
BRPI0801239A2 (pt) uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
BR112012030485A2 (pt) composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma
BR112013030282A2 (pt) composições compreendendo agente antibacteriano e tazobactama
BR112014027213A8 (pt) nova composição de alfentanil para o tratamento de dor aguda
BR112013026933A2 (pt) uso de uma combinação de pelo menos um carotenoide
BR112015030746A2 (pt) composição oral indicativa de limpeza dentária adequada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2506 DE 15-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.